Comparable stake leader
Randy Foong Soon Hong
SEC ownership of China SXT Pharmaceuticals, Inc.
Top holders, 13D/G large-stake signals, insider positions, and transaction flow tied to CIK 0001723980.
Disclosed value leader
Randy Foong Soon Hong
Comparable rows
4/7
Latest evidence
30 Jun 2026
- Public ticker
- SXTC on Nasdaq
- Parsed ownership sources
-
13D/G, 13F, and 3/4/5
Source: Parsed SEC ownership filingsUse: Compare filing families carefully
- Largest SEC-reported holder
-
Randy Foong Soon Hong
Ranking: Comparable ownership first, then disclosed value
- Comparable ownership rows
-
4 of 7
Meaning: Rows with safely comparable ownership %
- Latest 13D/G holder
-
Randy Foong Soon Hong
Source: Latest parsed Schedule 13D/G stake
- Latest parsed ownership date
-
30 Jun 2026
Freshness: Most recent filing date in this holder set
- Issuer CIK
- 0001723980
- Issuer location
- Taizhou
Ownership snapshot
CIK-linked ownership evidence from parsed SEC filings.
3 signals
Issuer
Names, identifiers, and filing context for this profile.
2 identity fields
Ownership snapshot
Top shareholders of China SXT Pharmaceuticals, Inc. (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Start with comparable ownership when available, then verify the linked 13F, 13D/G, or 3/4/5 evidence.
Comparable stake leader
Randy Foong Soon Hong
Disclosed value leader
Randy Foong Soon Hong
Comparable rows
4/7
Latest evidence
30 Jun 2026
13D/G
13F
3/4/5
Lead comparable stake: 9.1%
3 rows are not safely comparable across share classes.
13D/G row: Randy Foong Soon Hong
Quick read
Randy Foong Soon Hong leads the comparable SEC ownership view at 9.1%.
4 of 7 rows have a safely comparable ownership percentage. Use this as a filing-backed starting point, then open the detailed table for source links, reporting role, position value, share count, and filing date.
Open SEC evidence
Opens Randy Foong Soon Hong's linked filing trail.
Comparable ownership
Top 4
Randy Foong Soon Hong
9.1%
Soo Seng Tan
9%
Cheng Guan Tan
8.8%
Choon Hwa Ching
8.4%
Ownership % is shown only when SEC disclosures are safely comparable across share classes.
Detailed SEC evidence table Showing 1-7 of 7 holder rows
| Holder | Evidence | Ownership % | Position | 12M Net Δ | As of |
|---|---|---|---|---|---|
| Randy Foong Soon Hong |
13D/G
FOONG SOON HONG, RANDY
|
9.1%
|
$18,741,185
10,588,240 shares
|
$0 | 29 Jul 2025 |
| Soo Seng Tan |
13D/G
TAN SOO SENG
|
9%
|
$18,394,123
10,392,160 shares
|
$0 | 29 Jul 2025 |
| Cheng Guan Tan |
13D/G
TAN CHENG GUAN
|
8.8%
|
$18,047,062
10,196,080 shares
|
$0 | 29 Jul 2025 |
| Choon Hwa Ching |
13D/G
CHING CHOON HWA
|
8.4%
|
$17,352,938
9,803,920 shares
|
$0 | 29 Jul 2025 |
| Caitong International Asset Management Co., Ltd |
13F
Company
|
—
class O/S missing
|
$4
2 shares
|
— | 30 Jun 2026 |
| UBS Group AG |
13F
Company
|
—
class O/S missing
|
$2
1 shares
|
— | 30 Jun 2026 |
| Feng Felix Zhou |
3/4/5
Co-CEO and Director, Director
|
—
class O/S missing
|
—
4 shares
|
— | 04 Jul 2017 |
How to read this table
Rows are grouped by holder and ranked first by SEC-reported ownership % when it is safely comparable, then by disclosed holdings value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
Forms 3/4/5 flow
Insider trading overview
Insider buy and sell flow is broadly balanced over the last 12 months. No Buy or Sell transactions have been reported since 13 Sep 2025.
Buys
$0
Insiders: 0
Sells
$0
Insiders: 0
Net
$0
Shares: 0
Window
Last 12 months
4 rolling buckets
Buy value
Sell value
Shares: 0
Shares: 0
| Window (months) | Buy shares | Sell shares | Buy value | Sell value | Net value |
|---|---|---|---|---|---|
| 0-3 | 0 | 0 | $0 | $0 | $0 |
| 3-6 | 0 | 0 | $0 | $0 | $0 |
| 6-9 | 0 | 0 | $0 | $0 | $0 |
| 9-12 | 0 | 0 | $0 | $0 | $0 |
Reporting owners
Insider holders from Forms 3/4/5
Showing 1-7 of 7 reporting-owner rows connected to China SXT Pharmaceuticals, Inc.. Open a relationship link for the CIK-to-CIK filing trail.
Rows
7
Largest Forms 3/4/5 holder
Jun Zheng
Net 12M change
$0
Latest report
20 Jan 2025
| Name | Relationship | Holdings Value | Past Year Net Change | Change % | Valuation | Report Date |
|---|---|---|---|---|---|---|
| Jun Zheng | Director | Mixed | 31 Dec 2018 | |||
| Simon Lim Sze Beng | Co-Chief Executive Officer | Mixed | 20 Jan 2025 | |||
| Tong Tony Liu | Director | Mixed | 10 May 2022 | |||
| Xiaodong Ji | Director | Mixed | 22 May 2021 | |||
| Yong Lip Chee | Director | Mixed | 20 Jan 2025 | |||
| Feng Felix Zhou | Co-CEO and Director, Director | Mixed | 04 Jul 2017 | |||
| Xiaodong Sean Pan | Chief Financial Officer | Mixed | 31 Jan 2022 |
Recent insider transactions for China SXT Pharmaceuticals, Inc.
Showing up to 300 recent insider transactions from the last 12 months.
| Insider | Symbol | Class | Transaction | % | SEC-reported value | SEC-reported price | Shares | Shares owned | Date | Ownership |
|---|---|---|---|---|---|---|---|---|---|---|
| No insider transactions were found in the last 12 months for this issuer. | ||||||||||
* marks a reported price that did not pass the local price check.